Your account is not claimed yet. You can sign up with ORCID to claim your account.

Christopher A Klebanoff

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Venues

Nature medicine

Nature reviews. Clinical oncology

Nature reviews. Drug discovery

Science (New York, N.Y.)

Weill Cornell Medical College

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Weill Cornell Medical College Oct 1o 2016

United States

Assistant Professor :: Department of Medicine

Publications

Joris L Vos, Bharat Burman, Swati Jain, Conall W R Fitzgerald, Eric J Sherman, Lara A Dunn, James V Fetten, Loren S Michel, Anuja Kriplani, Kenneth K Ng, Juliana Eng, Vatche Tchekmedyian, Sofia Haque, Nora Katabi, Fengshen Kuo, Catherine Y Han, Zaineb Nadeem, Wei Yang, Vladimir Makarov, Raghvendra M Srivastava, Irina Ostrovnaya, Manu Prasad, Charlotte L Zuur, Nadeem Riaz, David G Pfister, Christopher A Klebanoff, Timothy A Chan, Alan L Ho, Luc G T Morris
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nature medicine (2023)
Christopher A Klebanoff, Smita S Chandran, Brian M Baker, Sergio A Quezada, Antoni Ribas
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature reviews. Drug discovery (2023)
Ryan Q Notti, Fei Yi, Søren Heissel, Henrik Molina, Christopher A Klebanoff, Thomas Walz
The resting state of the human T-cell receptor. bioRxiv : the preprint server for biology (2023)
Andrew Chow, Karlo Perica, Christopher A Klebanoff, Jedd D Wolchok
Clinical implications of T cell exhaustion for cancer immunotherapy. Nature reviews. Clinical oncology 19 (12) (2022)
Christopher A Klebanoff
T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen. Cancer immunology research 10 (8) (2022)
Smita S Chandran, Jiaqi Ma, Martin G Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi, Hannah Y Wen, Jorge S Reis-Filho, Paul Zumbo, Si Ning Fu, Lauren B Banks, Fei Yi, Enric Vercher, Iñaki Etxeberría, Watchain D Bestman, Arnaud Da Cruz Paula, Ilinca S Aricescu, Alexander E Drilon, Doron Betel, David A Scheinberg, Brian M Baker, Christopher A Klebanoff
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature medicine 28 (5) (2022)
Smita S Chandran, Christopher A Klebanoff
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological reviews 290 (1) (2020)
Suman Kumar Vodnala, Robert Eil, Rigel J Kishton, Madhusudhanan Sukumar, Tori N Yamamoto, Ngoc-Han Ha, Ping-Hsien Lee, Min Hwa Shin, Shashank J Patel, Zhiya Yu, Douglas C Palmer, Michael J Kruhlak, Xiaojing Liu, Jason W Locasale, Jing Huang, Rahul Roychoudhuri, Toren Finkel, Christopher A Klebanoff, Nicholas P Restifo
T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science (New York, N.Y.) 363 (6434) (2019)
Christopher A Klebanoff, Jedd D Wolchok
Shared cancer neoantigens: Making private matters public. The Journal of experimental medicine 215 (1) (2017)

Christopher A Klebanoff.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christopher A Klebanoff